TL;DR
Eli Lilly has captured the commercial upper hand in the United States through a major CVS Caremark formulary expansion, even as Novo Nordisk moves massive volumes of its new oral Wegovy pill. Meanwhile, clinical data from the American Diabetes Association (ADA) 2026 Scientific Sessions reveals a deepening technological divide, with Lilly's retatrutide achieving historic bariatric-level weight loss while a flock of challengers scramble to claim a viable third-place position.
PBM Realignment and the Financial Reality of Net Price Erosion
The commercial duopoly is fracturing as Eli Lilly leverages formulary access to capture market share, while Novo Nordisk faces steep net pricing pressure despite record volume.
"Following this financial milestone, Lilly secured a major commercial victory on May 28, 2026, when CVS Caremark announced it would stop giving Novo Nordisk's Wegovy exclusive preferred status."
— eli-lilly-q1-2026-blowout-cvs-formulary-victory
(Source: CVS obesity drug deal puts Lilly on equal footing with Novo)
"US Operations Adjusted Sales decreased by 11% at CER, illustrating significant net price erosion in the competitive U.S. commercial landscape."
— novo-nordisk-q1-2026-results-wegovy-pill-milestone
(Source: Novo Nordisk Raises 2026 Outlook as Wegovy® Pill Delivers Record GLP-1 Launch Performance)
While Novo Nordisk can boast massive patient uptake with its oral Wegovy pill, the underlying commercial reality is that intense competition is driving down realized prices. Eli Lilly’s ability to place Zepbound and its new oral drug Foundayo on major PBM formularies will further squeeze Novo's margins in the crucial US market.
What to watch: Watch how Novo Nordisk's US revenues respond in the latter half of the year as CVS Caremark's removal of Wegovy's exclusive status and the addition of Lilly's options take full commercial effect eli-lilly-q1-2026-blowout-cvs-formulary-victory.
The Efficacy Arms Race Reaches Bariatric Levels
Next-generation metabolic therapies are pushing past simple weight loss to target bariatric-level efficacy and specific comorbidity resolution.
"Nearly half (45.3%) of the participants on the 12 mg dose achieved 30% or greater weight loss, a threshold historically reached only via bariatric surgery."
— lilly-retatrutide-phase-3-triumph-data
(Source: Retatrutide Delivers Bariatric-Level Weight Loss in Pivotal Phase 3 TRIUMPH-1 Trial)
Eli Lilly's triple agonist, retatrutide, is redefining the ceiling of pharmacological therapy by matching surgical weight-loss outcomes and simultaneously resolving sleep apnea and joint pain. This raises the competitive bar so high that dual-action therapies like Novo Nordisk's CagriSema must now prove multi-organ benefits, rather than just raw weight reduction, to justify their clinical space.
What to watch: Watch whether Lilly's planned regulatory submissions for retatrutide lead to a rapid FDA review based on its unprecedented comorbidity resolution data lilly-retatrutide-phase-3-triumph-data.
The Scramble for the Third-Place Wedge
Outside the dominant duopoly, a crowded field of clinical-stage biotechs and mid-tier pharmas is trying to carve out specialized niches to avoid direct price competition.
"Zealand reported that the majority of weight reduction was due to fat loss, with lean muscle mass accounting for 'only a small proportion' of lost mass."
— glp1-competitive-landscape-ada-2026 (Source: Boehringer dual-acting obesity shot hits mark in Phase 3 trial)
Because challengers cannot match the sheer scale or raw efficacy of Lilly's and Novo's lead assets, they are pivoting toward specialized benefits like muscle preservation, monthly dosing, or oral convenience. Roche's dual agonist and Structure's aleniglipron show that there is still room for high-efficacy alternatives, but these players must offer distinct clinical advantages to avoid being sidelined as commodity options.
What to watch: Watch whether Viking Therapeutics' oral formulation successfully transitions into late-stage trials to challenge the oral market glp1-competitive-landscape-ada-2026.
What surprised us
- The Hidden Net Pricing Decay at Novo Nordisk: Despite Novo Nordisk celebrating the massive, rapid launch of its oral Wegovy pill, its underlying US financial performance was surprisingly weak novo-nordisk-q1-2026-results-wegovy-pill-milestone. Strip away a massive one-time 340B provision reversal of DKK 29.2 billion, and Novo's adjusted net sales actually fell by 4%, showing just how brutally competitive pricing has become in the US commercial market novo-nordisk-q1-2026-results-wegovy-pill-milestone.
- Retatrutide's Bariatric-Beating Tail: In an extension of Lilly’s TRIUMPH-1 study, patients on the highest dose of retatrutide did not hit a weight-loss plateau even at 80 weeks, ultimately achieving an average weight loss of 30.3% at 104 weeks lilly-retatrutide-phase-3-triumph-data. This suggests the drug's glucagon receptor activation continues to boost energy expenditure long after standard appetite suppression has normalized.
- Muscle-Sparing as the New Competitive Frontier: Boehringer Ingelheim and Zealand Pharma's survodutide did not post the highest weight-loss numbers at the ADA sessions, but their focus on "quality of weight loss" is a brilliant tactical pivot glp1-competitive-landscape-ada-2026. By demonstrating that muscle mass was largely spared during fat loss, they have carved out a highly defensible niche that could protect them from the pricing wars of the broader duopoly glp1-competitive-landscape-ada-2026.
Open threads worth a vote
[GLP-1 Ripple Effects: Food & Beverage, Medtech, and Insurance Dynamics](/topics/019e84f3-e46c-7c64-bcce-6d0ef82f7c3f#threads)
Since last time
- Escalated — PBM and Formulary Realignments: While we previously focused on the tactical battle for formulary access, the narrative has shifted to the financial fallout. The focus is now on net price erosion and the duopoly’s fracturing financials.
- Promoted — The Clinical Efficacy Arms Race: Previously unmentioned, the focus has shifted to the ADA 2026 Scientific Sessions, specifically Lilly’s retatrutide and its bariatric-level efficacy.
- Promoted — The Scramble for the Third-Place Wedge: Previously unmentioned, we are now tracking the biotech/mid-tier pharma pivot toward specialized niches (muscle sparing, oral convenience).
- Disappeared — Federal Policy Interventions: The Medicare GLP-1 Bridge program is no longer a focus.
- Disappeared — Medtech/Bariatric Surgery Disruption: The impact on surgical volumes is no longer a focus.
- Unchanged — Open Threads: The previous thread on ripple effects remains open.
PBM Realignment and the Financial Reality of Net Price Erosion [Escalated]
The commercial battle between Eli Lilly and Novo Nordisk has moved beyond simple formulary inclusion into a war of attrition on net pricing. While the CVS Caremark formulary win for Lilly is the primary tactical update, the real story is the resulting financial pressure on Novo Nordisk.
"Following this financial milestone, Lilly secured a major commercial victory on May 28, 2026, when CVS Caremark announced it would stop giving Novo Nordisk's Wegovy exclusive preferred status."
— eli-lilly-q1-2026-blowout-cvs-formulary-victory (Source: CVS obesity drug deal puts Lilly on equal footing with Novo)
"US Operations Adjusted Sales decreased by 11% at CER, illustrating significant net price erosion in the competitive U.S. commercial landscape."
— novo-nordisk-q1-2026-results-wegovy-pill-milestone (Source: Novo Nordisk Raises 2026 Outlook as Wegovy® Pill Delivers Record GLP-1 Launch Performance)
What to watch: Watch how Novo Nordisk's US revenues respond in the latter half of the year as CVS Caremark's removal of Wegovy's exclusive status and the addition of Lilly's options take full commercial effect.
The Efficacy Arms Race Reaches Bariatric Levels [Promoted]
The competitive ceiling has been raised. New clinical data indicates that next-generation therapies are no longer just competing for weight loss, but for the specific comorbidity resolution previously reserved for surgery.
"Nearly half (45.3%) of the participants on the 12 mg dose achieved 30% or greater weight loss, a threshold historically reached only via bariatric surgery."
— lilly-retatrutide-phase-3-triumph-data (Source: Retatrutide Delivers Bariatric-Level Weight Loss in Pivotal Phase 3 TRIUMPH-1 Trial)
Eli Lilly's retatrutide is setting a new bar, forcing competitors like Novo Nordisk to prove multi-organ benefits rather than just raw weight reduction.
What to watch: Watch whether Lilly's planned regulatory submissions for retatrutide lead to a rapid FDA review based on its unprecedented comorbidity resolution data.
The Scramble for the Third-Place Wedge [Promoted]
With the duopoly dominating the market, smaller players are pivoting to avoid direct price competition. The focus is now on "quality of weight loss" and specialized delivery mechanisms.
"Zealand reported that the majority of weight reduction was due to fat loss, with lean muscle mass accounting for 'only a small proportion' of lost mass."
— glp1-competitive-landscape-ada-2026 (Source: Boehringer dual-acting obesity shot hits mark in Phase 3 trial)
Players like Roche and Structure are prioritizing muscle preservation and oral convenience to carve out defensible niches.
What to watch: Watch whether Viking Therapeutics' oral formulation successfully transitions into late-stage trials to challenge the oral market.
What surprised us
- The Hidden Net Pricing Decay at Novo Nordisk [NEW]: Despite the massive launch of the oral Wegovy pill, Novo’s underlying US financial performance was weak. Excluding a one-time 340B provision reversal, adjusted net sales actually fell by 4% novo-nordisk-q1-2026-results-wegovy-pill-milestone.
- Retatrutide's Bariatric-Beating Tail [NEW]: In the TRIUMPH-1 study extension, patients on the highest dose did not plateau, achieving 30.3% weight loss at 104 weeks, suggesting sustained glucagon receptor activation lilly-retatrutide-phase-3-triumph-data.
- Muscle-Sparing as the New Competitive Frontier [NEW]: Boehringer Ingelheim and Zealand Pharma’s survodutide focus on "quality of weight loss" is a tactical pivot that creates a defensible niche against the broader duopoly glp1-competitive-landscape-ada-2026.
Open threads
[GLP-1 Ripple Effects: Food & Beverage, Medtech, and Insurance Dynamics](/topics/019e84f3-e46c-7c64-bcce-6d0ef82f7c3f#threads) (Carried over from previous briefing).